|
|
肝细胞癌合并门静脉癌栓的治疗进展
|
Abstract:
肝细胞癌为临床常见的恶性肿瘤，其高度恶性及易于侵犯和转移的生物学特性，致使患者生存率极低，其中最常见也是临床最棘手的一种情况是肝细胞癌合并门静脉癌栓，通常这类患者病情进展迅速，其治愈率极低，因此这类患者死亡率极高，而生存率极低。现阶段随着医疗水平和科学技术进步，肝细胞癌的相关治疗取得了显著进展，对于肝细胞癌的治疗也是采用多学科综合治疗模式，对于各期肝癌患者制定个体化治疗方案，采用联合治疗疗法，最大化改善患者的生活治疗和生存率。本文将从现有的治疗方法论述其在肝细胞癌治疗过程中的应用。
Hepatocellular carcinoma is a common clinical malignant tumor. Its highly malignant and prone to invasion and metastasis biological characteristics result in extremely low patient survival rates. One of the most common and clinically difficult conditions is hepatocellular carcinoma complicated with portal vein cancer. Suppository usually progresses rapidly in such patients, and its cure rate is extremely low. Therefore, the mortality rate of such patients is extremely high, and the survival rate is extremely low. At this stage, with the advancement of medical level and science and technology, significant progress has been made in the treatment of hepatocellular carcinoma. The treatment of hepatocellular carcinoma also adopts a multidisciplinary comprehensive treatment model. Individualized treatment plans are developed for patients with liver cancer at various stages, and combined therapy is adopted to maximize the improvement of patients’ life treatment and survival rate. This article will discuss its application in the treatment of hepatocellular carcinoma from the existing treatment methods.
| [1] | 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版) [J]. 中华肝脏病杂志, 2017, 25(12): 886-895. |
| [2] | 杨敏, 王延风, 徐海燕, 等. 中晚期原发性肝癌住院患者死亡危险因素分析[J]. 中国肿瘤, 2016, 25(6): 438-441. |
| [3] | Wang, K., Guo, W.X., Chen, M.S., et al. (2016) Multimodality Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Matching Score Analysis. Medicine, 95, e3015.
https://doi.org/10.1097/MD.0000000000003015 |
| [4] | 张修平, 王康, 钟承千, 等. 浅谈肝细胞癌合并门静脉癌栓的手术治疗[J]. 肝胆外科杂志, 2017, 25(1): 14-17. |
| [5] | Kokudo, T., Hasegawa, K., Matsuyama, Y., et al. (2016) Survival Benefit of Liver Resection for Hepatocellular Carcinoma Associated with Portal Vein Invasion. Journal of Hepatology, 65, 938-943.
https://doi.org/10.1016/j.jhep.2016.05.044 |
| [6] | Lee, J.M., Jang, B.K., Lee, Y.J., et al. (2016) Survival Outcomes of Hepatic Resection Compared with Transarterial Chemoembolization or Sorafenib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Clinical and Molecular Hepatology, 22, 160-167. https://doi.org/10.3350/cmh.2016.22.1.160 |
| [7] | Inoue, Y., Hasegawa, K., Ishizawa, T., et al. (2009) Is There Any Difference in Survival According to the Portal Tumor Thrombectomy Method in Patients with Hepatocellular Carcinoma. Surgery, 145, 9-19.
https://doi.org/10.1016/j.surg.2008.09.005 |
| [8] | Qin, S. (2012) Primary Liver Cancer Diagnosis and Treatment Expert Panel of the Chinese Ministry of Health. Guidelines on the Diagnosis and Treatment of Primary Liver Cancer (2011 Edition). Chinese Clinical Oncology, 1, 10. |
| [9] | Hennedige, T. and Venkatesh, S.K. (2016) Advances in Computed Tomography and Magnetic Resonance Imaging of Hepato-Cellular Carcinoma. World Journal of Gastroenterology, 22, 205-220. https://doi.org/10.3748/wjg.v22.i1.205 |
| [10] | Grandhi, M.S., Kim, A.K., Ronnekleiv-Kelly, S.M., et al. (2016) Hepatocellular Carcinoma: From Diagnosis to Treatment. Surgical Oncology, 25, 74-85. https://doi.org/10.1016/j.suronc.2016.03.002 |
| [11] | Ye, J.Z., Zhang, Y.Q., Ye, H.H., et al. (2014) Appropriate Treatment Strategies Improve Survival of Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus. World Journal of Gastroenterology, 20, 17141-17147.
https://doi.org/10.3748/wjg.v20.i45.17141 |
| [12] | Cheng, S., Chen, M., Cai, J., et al. (2017) Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portalvein Tumor Thrombus: 2016 Edition. Oncotarget, 8, 8867-8876.
https://doi.org/10.18632/oncotarget.12817 |
| [13] | Itoh, S., Shirabe, K., Taketomi, A., et al. (2012) Zero Mortality in More than 300 Hepatic Resections: Validity of Preoperative Volumetric Analysis. Surgery Today, 42, 435-440. https://doi.org/10.1007/s00595-011-0108-2 |
| [14] | Zhang, Z.M., Lai, E.C., Zhang, C., et al. (2015) The Strategies for Treating Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. International Journal of Surgery, 20, 8-16. https://doi.org/10.1016/j.ijsu.2015.05.009 |
| [15] | Znang, X.P., Wang, K., Li, N., et al. (2017) Survival Benefit of Hepatic Resection versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. BMC Cancer, 17, Article No. 902. https://doi.org/10.1186/s12885-017-3895-z |
| [16] | Liu, S., Guo, L., Li, H., et al. (2018) Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. Annals of Surgical Oncology, 25, 2098-2104.
https://doi.org/10.1245/s10434-018-6438-1 |
| [17] | Wei, X.B., Jiang, Y.B., Zhang, X.P., et al. (2019) Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. Journal of Clinical Oncology, 37, 2141-2151. https://doi.org/10.1200/JCO.18.02184 |
| [18] | European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. |
| [19] | Bi, F., Qin, S., Gu, S., et al. (2020) Donafenib versus Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: An Open-Label, Randomized, Multicenter Phase II/III Trial. Journal of Clinical Oncology, 38, 4506.
https://doi.org/10.1200/JCO.2020.38.15_suppl.4506 |
| [20] | He, M.K., Li, Q.J., Zou, R.H., et al. (2019) Sorafenib plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250 |
| [21] | El-Khoueiry, A.B., Sangro, B., Yau, T., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2 |
| [22] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版) [J]. 肿瘤综合治疗电子杂志, 2020, 6(2): 55-85. |
| [23] | Zhu, A.X., Finn, R.S., Edeline, J., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. https://doi.org/10.1016/S1470-2045(18)30351-6 |
| [24] | Fan, W.Z., Yuan, G.S., Fan, H.S., et al. (2019) Apatinib Combined with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clinical Therapeutics, 41, 1463-1476. https://doi.org/10.1016/j.clinthera.2019.04.036 |
| [25] | (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. https://doi.org/10.1016/j.jhep.2018.03.019 |
| [26] | Cheng, S.Q., Chen, M.S., Cai, J.J., et al. (2020) Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer, 9, 28-40.
https://doi.org/10.1159/000503685 |
| [27] | Cerrito, L., Annicchiarico, B.E., Iezzi, R., et al. (2019) Treatment of Hepatocellular Carcinoma in Patients with Portal Vein Tumor Thrombosis: Beyond the Known Frontiers. World Journal of Gastroenterology, 25, 4360-4382.
https://doi.org/10.3748/wjg.v25.i31.4360 |
| [28] | Choi, J.W., Kim, H.C., Lee, J.H., et al. (2017) Transarterial Chemoembolization of Hepatocellular Carcinoma with Segmental Portal vein Tumour Thrombus. European Radiology, 27, 1448-1458.
https://doi.org/10.1007/s00330-016-4511-3 |
| [29] | Silva, J.P., Berger, N.G., Tsai, S., et al. (2017) Transarterial Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis. HPB (Oxford), 19, 659-666.
https://doi.org/10.1016/j.hpb.2017.04.016 |
| [30] | 兰蓝, 赵飞, 蔡玥, 等. 中国居民2015年恶性肿瘤死亡率流行病学特征分析[J]. 中华流行病学杂志, 2018, 39(1): 32-34. |
| [31] | 程树群, 陈敏山, 蔡建强, 等. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版) [J]. 肝癌电子杂志, 2018, 5(2): 1-7. |
| [32] | Lv, W.F., Liu, K.C., Lu, D., et al. (2018) Transarterial Chemoembolization for Hepatocellular Carcinoma Combined with Portal Veintumor Thrombosis. Cancer Management and Research, 10, 4719-4726.
https://doi.org/10.2147/CMAR.S166527 |
| [33] | Tai, W.M.D., Loke, K.S.H., Gogna, A., et al. (2020) A Phase II Open-Label, Single-Center, Nonrandomized Trial of Y90-Radioembolization in Combination with Nivolumab in Asian Patients with Advanced Hepatocellular Carcinoma: CA 209-678. Journal of Clinical Oncology, 38, 4590. https://doi.org/10.1200/JCO.2020.38.15_suppl.4590 |
| [34] | Hoi, J.W., Kim, H.C., Lee, J.H., et al. (2017) Transarterial Chemoembolization of Hepatocellular Carcinoma with Segmental Portal vein Tumour Thrombus. European Radiology, 27, 1448-1458.
https://doi.org/10.1007/s00330-016-4511-3 |
